Overview

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel. A total of approximately 38 subjects will participate in this study, with approximately 19 subjects in Part 1 and approximately 19 subjects in Part 2. Each subject may only participate in one of the parts.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene Corporation

Treatments:

Hydroxyitraconazole
Itraconazole
Rifampin